165 related articles for article (PubMed ID: 16595824)
1. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria.
Aarsand AK; Petersen PH; Sandberg S
Clin Chem; 2006 Apr; 52(4):650-6. PubMed ID: 16595824
[TBL] [Abstract][Full Text] [Related]
2. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
[TBL] [Abstract][Full Text] [Related]
3. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families.
Kauppinen R; von und zu Fraunberg M
Clin Chem; 2002 Nov; 48(11):1891-900. PubMed ID: 12406973
[TBL] [Abstract][Full Text] [Related]
4. Acute intermittent porphyria in childhood: a population-based study.
Hultdin J; Schmauch A; Wikberg A; Dahlquist G; Andersson C
Acta Paediatr; 2003 May; 92(5):562-8. PubMed ID: 12839285
[TBL] [Abstract][Full Text] [Related]
5. A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen.
Zhang J; Yasuda M; Desnick RJ; Balwani M; Bishop D; Yu C
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2389-96. PubMed ID: 21783436
[TBL] [Abstract][Full Text] [Related]
6. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria.
Marsden JT; Rees DC
J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454
[TBL] [Abstract][Full Text] [Related]
7. Porphyrin precursors and risk of primary liver cancer in acute intermittent porphyria: A case-control study of 188 patients.
Lissing M; Wester A; Vassiliou D; Floderus Y; Harper P; Sardh E; Wahlin S
J Inherit Metab Dis; 2023 Nov; 46(6):1186-1194. PubMed ID: 37650859
[TBL] [Abstract][Full Text] [Related]
8. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
Sardh E; Harper P; Andersson DE; Floderus Y
Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
[TBL] [Abstract][Full Text] [Related]
9. Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model.
Vera-Yunca D; Serrano-Mendioroz I; Sampedro A; Jericó D; Trocóniz IF; Fontanellas A; Parra-Guillén ZP
Mol Genet Metab; 2019 Nov; 128(3):367-375. PubMed ID: 30639045
[TBL] [Abstract][Full Text] [Related]
10. Mass spectrometric characterisation of a condensation product between porphobilinogen and indolyl-3-acryloylglycine in urine of patients with acute intermittent porphyria.
Marcos J; Ibañez M; Ventura R; Segura J; To-Figueras J; Pozo OJ
J Mass Spectrom; 2015 Jul; 50(7):929-37. PubMed ID: 26349648
[TBL] [Abstract][Full Text] [Related]
11. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
Sardh E; Rejkjaer L; Andersson DE; Harper P
Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
[TBL] [Abstract][Full Text] [Related]
13. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
Unzu C; Sampedro A; Sardh E; Mauleón I; Enríquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
PLoS One; 2012; 7(3):e32978. PubMed ID: 22412963
[TBL] [Abstract][Full Text] [Related]
14. Individualized workup: a new approach to the biochemical diagnosis of acute attacks of neuroporphyria.
Schoenfeld N; Mamet R
Physiol Res; 2006; 55 Suppl 2():S103-108. PubMed ID: 17298214
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of glycerol and dextrose on porphyrin precursor excretion in acute intermittent porphyria.
Bonkowsky HL; Magnussen CR; Collins AR; Doherty JM; Hess RA; Tschudy DP
Metabolism; 1976 Apr; 25(4):405-14. PubMed ID: 1263834
[TBL] [Abstract][Full Text] [Related]
16. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
Johansson A; Möller C; Fogh J; Harper P
Mol Med; 2003; 9(9-12):193-9. PubMed ID: 15208740
[TBL] [Abstract][Full Text] [Related]
17. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes.
Sardh E; Andersson DE; Henrichson A; Harper P
Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):66-71. PubMed ID: 19268004
[TBL] [Abstract][Full Text] [Related]
18. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
[TBL] [Abstract][Full Text] [Related]
19. Studies in porphyria. IV. Expression of the gene defect of acute intermittent porphyria in cultured human skin fibroblasts and amniotic cells: prenatal diagnosis of the porphyric trait.
Sassa S; Solish G; Levere RD; Kappas A
J Exp Med; 1975 Sep; 142(3):722-31. PubMed ID: 1165472
[TBL] [Abstract][Full Text] [Related]
20. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
